6,656 Shares in Cytokinetics, Incorporated (NASDAQ:CYTK) Acquired by Eqis Capital Management Inc.

Eqis Capital Management Inc. bought a new stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTKGet Rating) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 6,656 shares of the biopharmaceutical company’s stock, valued at approximately $262,000.

Other institutional investors have also added to or reduced their stakes in the company. KBC Group NV purchased a new stake in Cytokinetics during the 1st quarter valued at $99,000. Captrust Financial Advisors boosted its stake in Cytokinetics by 79.8% during the 1st quarter. Captrust Financial Advisors now owns 3,910 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 1,735 shares during the last quarter. Advisor Group Holdings Inc. boosted its stake in Cytokinetics by 14.9% during the 1st quarter. Advisor Group Holdings Inc. now owns 5,930 shares of the biopharmaceutical company’s stock valued at $154,000 after purchasing an additional 767 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in Cytokinetics by 6.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 6,454 shares of the biopharmaceutical company’s stock valued at $236,000 after purchasing an additional 372 shares during the last quarter. Finally, Strs Ohio boosted its stake in Cytokinetics by 1,280.0% during the 2nd quarter. Strs Ohio now owns 6,900 shares of the biopharmaceutical company’s stock valued at $271,000 after purchasing an additional 6,400 shares during the last quarter.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Cantor Fitzgerald increased their target price on Cytokinetics from $56.00 to $69.00 in a research note on Monday, August 15th. UBS Group assumed coverage on Cytokinetics in a report on Tuesday, October 11th. They set a “buy” rating and a $80.00 price target on the stock. StockNews.com cut Cytokinetics from a “hold” rating to a “sell” rating in a report on Friday, November 4th. Mizuho assumed coverage on Cytokinetics in a report on Friday, September 2nd. They set a “buy” rating and a $80.00 price target on the stock. Finally, JMP Securities increased their price target on Cytokinetics from $53.00 to $82.00 and gave the company a “market outperform” rating in a report on Monday, October 3rd. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $63.83.

Cytokinetics Price Performance

NASDAQ:CYTK opened at $39.95 on Wednesday. The company has a quick ratio of 11.56, a current ratio of 11.56 and a debt-to-equity ratio of 1.77. The business’s 50-day simple moving average is $47.09 and its two-hundred day simple moving average is $45.07. The stock has a market cap of $3.78 billion, a PE ratio of -12.64 and a beta of 0.98. Cytokinetics, Incorporated has a 52 week low of $29.26 and a 52 week high of $55.80.

Insider Buying and Selling at Cytokinetics

In other Cytokinetics news, CAO Robert Wong sold 2,100 shares of the firm’s stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $40.68, for a total transaction of $85,428.00. Following the sale, the chief accounting officer now directly owns 30,537 shares of the company’s stock, valued at $1,242,245.16. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, Director John T. Henderson sold 21,759 shares of the firm’s stock in a transaction dated Monday, September 12th. The stock was sold at an average price of $54.94, for a total transaction of $1,195,439.46. Following the completion of the transaction, the director now owns 24,049 shares in the company, valued at $1,321,252.06. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Robert Wong sold 2,100 shares of the firm’s stock in a transaction dated Monday, November 14th. The shares were sold at an average price of $40.68, for a total value of $85,428.00. Following the transaction, the chief accounting officer now owns 30,537 shares of the company’s stock, valued at approximately $1,242,245.16. The disclosure for this sale can be found here. Insiders have sold a total of 120,872 shares of company stock valued at $5,975,182 over the last ninety days. 5.00% of the stock is currently owned by company insiders.

Cytokinetics Profile

(Get Rating)

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.

Read More

Want to see what other hedge funds are holding CYTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytokinetics, Incorporated (NASDAQ:CYTKGet Rating).

Institutional Ownership by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.